⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for paranasal sinus squamous cell carcinoma

Every month we try and update this database with for paranasal sinus squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerNCT01267240
Paranasal Sinus...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Oral ...
Stage IVA Oroph...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Oral ...
Stage IVB Oroph...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Oral ...
Stage IVC Oroph...
Capecitabine
Vorinostat
19 Years - National Cancer Institute (NCI)
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerNCT01267240
Paranasal Sinus...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Oral ...
Stage IVA Oroph...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Oral ...
Stage IVB Oroph...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Oral ...
Stage IVC Oroph...
Capecitabine
Vorinostat
19 Years - National Cancer Institute (NCI)
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaNCT03381183
Squamous Cell C...
Squamous Cell C...
Metastatic Squa...
Oral Cavity Squ...
Oropharynx Squa...
Paranasal Sinus...
Hypopharynx Squ...
Larynx Squamous...
Durvalumab
IRX-2 Regimen
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerNCT01267240
Paranasal Sinus...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Oral ...
Stage IVA Oroph...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Oral ...
Stage IVB Oroph...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Oral ...
Stage IVC Oroph...
Capecitabine
Vorinostat
19 Years - National Cancer Institute (NCI)
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaNCT03381183
Squamous Cell C...
Squamous Cell C...
Metastatic Squa...
Oral Cavity Squ...
Oropharynx Squa...
Paranasal Sinus...
Hypopharynx Squ...
Larynx Squamous...
Durvalumab
IRX-2 Regimen
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: